EBS · Emergent BioSolutions Inc.
$4.59
+0.10 (+2.23%)
At close · Aug 14
Market Cap
$235.34M
Shares
51.27M
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$4.59
Open$4.50
Day$4.45–4.67
52W close$4.45–13.90
Avg vol 30d1.1M
Short int10.0M · 19.6% float · 17.7d
Short vol63%
Last earningsAug 5, 2026
DataJan 2020–Aug 2026
Filing10-Q · Aug 6
Up next
Next earnings call
Nov 4, 2026
Est · unconfirmed
· in 11 wks
FQ3-26 quarter ends
~Sep 30, 2026
Est
filed Aug 6, 2026
AI Brief
TL;DR.
Bullish
Bearish
From the call
AI-generated from the earnings call and 8-K · may contain errors · not investment advice
Ask ALVIS about this →
Equibles Rating
blended score · not investment adviceOverall
Sell
SellHoldBuy
Technical
Strong Sell
Momentum
Very Weak
Sentiment
Bullish
Fundamentals
Strong
Quant / Vol
Very High
Market backdrop
VIX 14.3 · calm
Equity put/call 0.52
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
−51%
below
Price vs 50-day avg
−38%
below
RSI (14)
20
oversold
MACD trend
Negative
52-week position
1%
near low
Volume (OBV)
Confirms
volume backs price
Momentum
relative strength
1-month return
−40%
trailing
6-month return
−58%
trailing
YTD return
−63%
this year
Relative strength
−72%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $7 › 200d $9 — 200d above 50d
Institutional flow
Accumulating
+2% holders QoQ · +33 funds added
Insider flow
Flat
No net insider activity over 90 days
Short interest
Falling
19.56% of float · ▼ -3.0% MoM · 17.7 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
195 holders — near 3-yr high, broad support
Squeeze score
69
elevated · 0–100
Fundamentals
Revenue growth
−29%
Y/Y
Gross margin
43%
expanding
EPS growth
+126%
Y/Y
Free cash flow
$156.8M
Buyback
$37.5M
remaining
Balance sheet
$366.7M
net debt
Quant / Vol
risk profile
Volatility
78%
annualized · 1-yr
Max drawdown
−68%
past year
ATR
8.9%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Guidance & track record
Latest guidance
· from the 8-K filed Aug 5, 2026
full year 2026
Total revenues
$645M – $675M
Net loss
$-245M – $-225M
Adjusted net income
$10M – $30M
Adjusted EBITDA
$130M – $150M
Adjusted gross margin %
42% – 44%
Q3 2026
Total revenues
$110M – $130M
2026 Full Year Forecast
Gross margin
$200M – $226M
Product and services sales, net
$620M – $650M
Gross margin %
32% – 35%
Adjusted gross margin
$263M – $289M
FY 2026
SG&A
27% – 28%
Prior guidance
period ended
· from the 8-K filed Apr 30, 2026
Total revenues
· Q2 2026
$170M – $185M
Guided vs delivered
· last 1 settled
Q2 revenue
Q2 2024
guided $160M – $210M
$254.7M
Beat +37.7%
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Technicals
trend & momentum for long-term holders Strong Sell
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
−51%
Bearish
Price vs 50-day avg
−38%
Bearish
RSI (14)
20
Neutral
MACD trend
Negative
Bearish
52-week position
1%
Bearish
Volume (OBV)
Confirms
Neutral
Market signals — smart money & positioning
Bullish · 3 of 6
Trend (MA cross)
No cross
50d $7 › 200d $9 — 200d above 50d
Institutional flow
Accumulating
+2% holders QoQ · +33 funds added
Insider flow
Flat
No net insider activity over 90 days
Short interest
Falling
19.56% of float · ▼ -3.0% MoM · 17.7 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
195 holders — near 3-yr high, broad support
Price context
position in its 52-week range
Range low $4
Now $5 · 1%
Range high $14
vs 200-day avg -51%
vs 50-day avg -38%
Illustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
the company's own KPIs, from written earnings releases and filings| Metric | Latest | Period | YoY |
|---|---|---|---|
| Commercial Products Segment Revenue | $52.4M | FY2026 Q2 | -22.4% |
|
|
|||
| Depreciation - MCM Products segment | $4.3M | the three months ended June 30, 2026 filing | — |
| MCM Products Segment Revenue | $168M | FY2026 Q2 | +187.7% |
|
|
|||
| Total segment adjusted gross margin reportable segments non-GAAP | $132.3M | the three months ended June 30, 2026 filing | — |
| Adjusted EBITDA non-GAAP | $130M | 2026 Full Year Forecast | -44.1% |
|
|
|||
| Adjusted EBITDA margin non-GAAP | 34% | Six Months Ended June 30, 2026 | +17.2% |
|
|
|||
| Adjusted gross margin non-GAAP | $209.2M | Six Months Ended June 30, 2026 | — |
|
|
|||
| Adjusted net income non-GAAP | $42.8M | Six Months Ended June 30, 2026 | — |
|
|
|||
| Adjusted net income per diluted share non-GAAP | $0.83 | Six Months Ended June 30, 2026 | — |
|
|
|||
| Capital expenditures | $2.1M | Q2 2026 | -27.6% |
|
|
|||
| Capital expenditures as a % of total revenues | 1% | Q2 2026 | — |
|
|
|||
| MCM Product gross margin percentage | 61% | six months ended June 30, 2026 | — |
| Net Debt non-GAAP | $450M | As of June 30, 2026 | +4.0% |
|
|
|||
| Segment adjusted gross margin - MCM Products non-GAAP | $116.1M | Q2 2026 | — |
| Cash balance | $160M | Q1 2026 | — |
| Liquidity | $260M | Q1 2026 | — |
|
|
|||
| Net Leverage Ratio non-GAAP | 2.4 | Twelve months ended March 31, 2026 | +26.3% |
|
|
|||
| Trailing Twelve Month Adjusted EBITDA non-GAAP | $177.7M | Twelve months ended March 31, 2026 | -8.3% |
|
|
|||
| Adjusted net income (loss) non-GAAP | -$12.1M | Year Ended December 31, 2025 | — |
|
|
|||
| Int'l MCM sales percentage of total MCM revenue | 34% | FY 2025 | — |
| Normalized Revenues non-GAAP | $742.9M | As of December 31, 2025 | — |
| Total adjusted gross margin % non-GAAP | 54% | Full Year 2025 | — |
| Cash | $246M | Q3 2025 | — |
| Employees | 900 | FY 2025 | — |
| MCM contract mods and orders | 11 | YTD 2025 | — |
| NARCAN® Nasal Spray unit volume | 13% | Q3 2025 | — |
| Shares repurchased | 1.1M | Q3 2025 | — |
|
|
|||
| Shares repurchased YTD | 2.3M | YTD 2025 | — |
| Share repurchase amount | $6.9M | Q2 2025 | — |
| Gross Margin % | 50% | Q1 2025 | — |
|
|
|||
| MCM Products segment adjusted gross margin non-GAAP | $107.4M | Q1 2025 | — |
|
|
|||
| Commercial Products segment adjusted gross margin non-GAAP | $213M | Full Year 2024 | — |
|
|
|||
| Services segment adjusted gross margin non-GAAP | -$60.7M | Full Year 2024 | — |
|
|
|||
| Total Segment Adjusted Gross Margin % non-GAAP | 45% | Full Year 2024 | +36.4% |
|
|
|||
| Total Segment Gross Margin % | 29% | Q4 2024 | -6.5% |
|
|
|||
| Adjusted net loss non-GAAP | -$273M | Nine Months Ended September 30, 2024 | — |
| Adjusted net loss per diluted share non-GAAP | -$5.36 | Nine Months Ended September 30, 2024 | — |
| Net Working Capital | $282.4M | As of September 30, 2024 | — |
| Total segment revenues non-GAAP | $283.8M | Q3 2024 | — |
|
|
|||
| Current Emergent employees expected to join Bora as part of the transaction | 350 | the three months ended June 30, 2024 filing | — |
| Loss on assets held for sale | $40M | the three months ended June 30, 2024 filing | — |
| Non-cash impairment charge | $27.2M | the three months ended June 30, 2024 filing | — |
| Total impairment of long-lived assets | $27.2M | Three Months Ended June 30, 2024 filing | — |
| Total restructuring costs | $17.1M | Three Months Ended June 30, 2024 filing | — |
| Operating Cash Flow | -$15.1M | Six Months Ended June 30, 2024 | — |
| Segment adjusted gross margin % non-GAAP | 56% | the three months ended March 31, 2024 filing | — |
| SG&A as a percentage of total revenue | 28% | the three months ended March 31, 2024 filing | — |
| Commercial Products Adjusted gross margin non-GAAP | $287M | Year Ended December 31, 2023 | — |
| Commercial Products gross margin % | 55% | Three Months Ended December 31, 2023 | — |
| MCM Products Adjusted gross margin non-GAAP | $151.3M | Year Ended December 31, 2023 | — |
| MCM Products gross margin % | 30% | Three Months Ended December 31, 2023 | — |
| Net capital expenditures | $11.4M | Q4 2023 | — |
| Services Adjusted gross margin non-GAAP | -$16.7M | Three Months Ended December 31, 2023 | — |
|
|
|||
| Services gross margin % | -82% | Three Months Ended December 31, 2023 | — |
| Services Segment Revenue | $78.5M | FY 2023 | — |
| Services adjusted gross margin percentage non-GAAP | -155% | Three Months Ended September 30, 2023 filing | — |
| Adjusted Cost of Sales non-GAAP | $164.8M | Three Months Ended September 30, 2023 | — |
|
|
|||
| Adjusted R&D as % of Adjusted Revenue non-GAAP | 8% | Nine Months Ended September 30, 2023 | — |
| Adjusted R&D expenses non-GAAP | $62.4M | Nine Months Ended September 30, 2023 | — |
|
|
|||
| Adjusted Revenues non-GAAP | $753.9M | Nine Months Ended September 30, 2023 | — |
|
|
|||
| Consolidated adjusted gross margin non-GAAP | $143M | Three Months Ended June 30, 2023 filing | — |
|
|
|||
| Gain on sale of business | $74.9M | Three Months Ended June 30, 2023 filing | — |
| Impairment of long-lived assets | -$306.7M | Three Months Ended June 30, 2023 filing | — |
| Products adjusted gross margin non-GAAP | $169.6M | Three Months Ended June 30, 2023 filing | — |
|
|
|||
| Adjusted COGS non-GAAP | $339.9M | Six Months Ended June 30, 2023 | — |
| Adjusted Loss per Diluted Share non-GAAP | -$4.21 | YTD 2023 | — |
| Product gross margin percentage | 47% | Six Months Ended June 30 | — |
| Products segment Adjusted cost of sales non-GAAP | $232M | Six Months Ended June 30, 2023 | — |
| Products segment Adjusted gross margin non-GAAP | $213.6M | Six Months Ended June 30, 2023 | — |
| Services gross margin percentage | -144% | Six Months Ended June 30 | — |
| Services segment Adjusted cost of sales non-GAAP | $55.7M | Q2 2023 | — |
| charges in connection with the 2023 Plan | $9.7M | the three months ended March 31, 2023 filing | — |
| Adjusted research and development expenses non-GAAP | $34.1M | Q1 2023 | — |
| Capital Expenditures (Net) | 113.3M | For the Twelve Months Ended December 31, 2022 | — |
Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period
Versus peers
Drug Manufacturers - Specialty & Generic — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
EBS
this stock
Emergent BioSolutions Inc.
|
$235.34M | -62.9% | -28.8% | — | 19.6% |
|
JHPCY
Jiangsu Hengrui Pharmaceuticals Co., Ltd./ADR
|
$64.91B | — | — | — | 0.0% |
|
TAK
Takeda Pharmaceutical Co Ltd
|
$56.30B | +13.1% | — | — | 0.1% |
|
GALDY
Galderma Group AG/ADR
|
$49.59B | +2.4% | — | — | 0.0% |
|
TEVA
Teva Pharmaceutical Industries Ltd
|
$42.85B | +17.8% | +4.3% | 60.3 | 2.9% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Smart Money
Financials
Filings
Earnings & Events
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| EBS | -5.2% | -39.8% | -58.1% | -36.4% | -62.9% |
| SPY | +0.4% | +4.5% | +13.8% | +3.9% | +13.9% |
| vs SPY | -5.6% | -44.3% | -71.9% | -40.4% | -76.7% |
Capital returns
Buyback program
· as of Jun 30, 2026
Authorized
$50.00M
Spent (derived)
$12.50M
Remaining
$37.50M
Spent
Remaining
Dividends per share over the trailing 365 days by ex-date · buyback figures as last reported in SEC filings ("spent" derived as authorized − remaining; when several programs run concurrently, authorized is their combined total per the newest filing) · components shown separately — trailing-year buyback spend isn't tracked, so no combined shareholder yield is derived.
Key facts
CIK
1367644
CUSIP
29089Q105
13F (30d)
188 filings
185 filers
Visit website
Investor relations